Prothena Co. plc (NASDAQ:PRTA) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its stake in Prothena Co. plc (NASDAQ:PRTA) by 74.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,087 shares of the biotechnology company’s stock after selling 40,485 shares during the quarter. SG Americas Securities LLC’s holdings in Prothena were worth $236,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. DCF Advisers LLC boosted its position in Prothena by 0.5% during the second quarter. DCF Advisers LLC now owns 107,500 shares of the biotechnology company’s stock worth $2,219,000 after acquiring an additional 500 shares during the last quarter. Signaturefd LLC boosted its position in Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 863 shares during the last quarter. ProShare Advisors LLC boosted its position in Prothena by 8.9% during the first quarter. ProShare Advisors LLC now owns 11,346 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 932 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Prothena by 265.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 1,122 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Prothena by 13.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after acquiring an additional 1,186 shares during the last quarter. Institutional investors and hedge funds own 97.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PRTA. HC Wainwright reaffirmed a “buy” rating and set a $84.00 target price on shares of Prothena in a research note on Tuesday, October 1st. Royal Bank of Canada lowered their price target on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. StockNews.com upgraded shares of Prothena from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Bank of America lowered their target price on shares of Prothena from $33.00 to $31.00 and set a “neutral” rating for the company in a report on Tuesday, October 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research report on Monday, September 30th. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $61.86.

Prothena Trading Down 3.6 %

Shares of NASDAQ PRTA opened at $16.50 on Tuesday. The stock has a market cap of $887.24 million, a price-to-earnings ratio of -5.08 and a beta of 0.17. Prothena Co. plc has a 52 week low of $15.52 and a 52 week high of $44.20. The company’s 50-day moving average price is $19.80 and its 200 day moving average price is $20.96.

Prothena (NASDAQ:PRTA) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 EPS for the quarter, beating analysts’ consensus estimates of ($1.01) by $2.23. The firm had revenue of $132.01 million for the quarter, compared to analysts’ expectations of $10.73 million. Prothena had a negative net margin of 23.44% and a negative return on equity of 9.00%. The firm’s revenue was up 3184.7% on a year-over-year basis. During the same period in the prior year, the company earned ($1.03) EPS. As a group, research analysts expect that Prothena Co. plc will post -2.34 earnings per share for the current year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.